Analyst Ratings for Myriad Genetics (MYGN) [Neutrals]
MYGN Rating Summary
MYGN Price Target Summary
- Highest: $31.00 (Goldman Sachs)
- Lowest: $17.00 (JPMorgan)
- Average: $23.25
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$23.25 (+28.5%)
* Over Last 12-Mos
Rating Score: 2.9 / 10
Percentile Rank: 24%
Avg. $ Target:
$23.25 (+28.5%)
* Over Last 12-Mos
Rating Score: 2.9 / 10
Percentile Rank: 24%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/21/2023 | Piper Sandler | Jon Peterson | New Coverage | Neutral (N/A) |
23.00 (N/A) |
21.32 (18.09) |
-15.15% | Details |
| 12/19/2023 | Wells Fargo | N/A | New Coverage | Equal Weight (N/A) |
20.00 (N/A) |
20.45 (18.09) |
-11.54% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
